Dr. Reddy';s Laboratories Announces the Launch of Its Authorized Generic Version of VASOSTRICT® (vasopressin injection, USP) Vials in the U.S. Market

Rhea-AI Summary

Dr. Reddy's Laboratories Ltd. has launched its authorized generic version of VASOSTRICT® (vasopressin injection, USP) in the U.S. This release, approved by the U.S. Food and Drug Administration, responds to a significant market demand, with the VASOSTRICT® brand generating approximately $878.5 million in U.S. sales over the past twelve months ending December 2021.

The product is supplied in a carton of 25 single-dose vials, each containing vasopressin 1 mL at 20 units/mL. This launch is particularly relevant during the ongoing COVID-19 pandemic.

Positive

• Launch of an authorized generic version of VASOSTRICT® in the U.S.
• Market potential with approximately $878.5 million in U.S. sales over the last year.

Negative

• None.

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of its authorized generic version of Par Pharmaceutical’s VASOSTRICT® (vasopressin injection, USP) Vials in the U.S. Market approved by the U.S. Food and Drug Administration (USFDA).

“We are pleased to provide this important authorized generic product to patients, especially in these difficult times of COVID-19,” says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories Inc.

The VASOSTRICT® brand market had U.S. sales of approximately $878.5 million MAT for the most recent twelve months ending in December 2021 according to IQVIA Health*.

Dr. Reddy’s Vasopressin Injection, USP, is supplied in a carton of 25 single-dose vials each containing vasopressin 1 mL at 20 units/mL.

Please click here for full prescribing information.

Vasostrict® is a trademark of Par Pharmaceutical Inc.

*IQVIA Retail and Non-Retail MAT December 2021

RDY-1221-385

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2021. The company assumes no obligation to update any information contained herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220209005725/en/

Investor Relations

Amit Agarwal

amita@drreddys.com

Media Relations

Usha Iyer

ushaiyer@drreddys.com

Source: Dr. Reddy’s Laboratories Ltd.

FAQ

What is the significance of Dr. Reddy's new authorized generic product RDY?

Dr. Reddy's launched its authorized generic version of VASOSTRICT®, addressing a substantial market demand worth approximately $878.5 million.

When was Dr. Reddy's VASOSTRICT® authorized generic launched?

The authorized generic version of VASOSTRICT® was launched recently in the U.S. market as approved by the USFDA.

How is Dr. Reddy's VASOSTRICT® product packaged?

The VASOSTRICT® product is supplied in cartons containing 25 single-dose vials, each with vasopressin 1 mL at 20 units/mL.

What are the recent sales figures for VASOSTRICT®?

The VASOSTRICT® brand achieved U.S. sales of approximately $878.5 million for the twelve months ending December 2021.